BREAKING from NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.

Today Nature Medicine! 🗞️ TILs Tumor Infiltrating Lymphocytes🔴🟠🟢 ➖a cell-based therapy for patients with colorectal & GI cancers➡️#immunotherapy. Responses➕“survivors” ➡️black arrows. 4️⃣>48-month survival ≈ CURES. Pembro⬆️responses. OncoAlert nature.com/articles/s4159…

Presented at #AACR25: Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: nej.md/3EsWcoi  AACR

👀Adjuvant aspirin 160 mg for 3 years- now in NCCN for patients with PIK3CA mutated #ColorectalCancer 👉ALASCCA trial showed ⬇️ 3-year recurrence. 👉Results even more impressive in patients with PIK3R1 and PTEN mutant cancers (+DFS benefit) ❓How are oncologists obtaining this

(1/6) Hot off the press in Nature Communications! Pembrolizumab delivers durable responses for patients with localized dMMR/MSI-H solid tumors. 🔗nature.com/articles/s4146…

🌟 DOUBLING of OS for adding encorafenib + cetuximab to FOLFOX in frontline treatment for (MSS) BRAF V600E mCRC!! ‼️ Providers should be testing for BRAF V600E mutations ASAP upon diagnosis of met CRC to identify pts who may benefit from this regimen!! 🙏 Grateful to be a

Devastating cut to National Cancer Institute budget - sad to see US cancer research de-prioritized in this time of tremendous potential and innovation #ASCO25

#ASCO25 ASCO NEJM ✅ Exercise Saves Lives After Colon Cancer ➡️ come watch Dr Chris Booth present the results of the ph3 CO.21 CHALLENGE study - don’t walk, run! 🏃🏃🏻‍♂️🏃 Hall B1 430-6pm 🙏 to our patients, my GI group CCTG 🇨🇦 and our partner GI Cancer Institute and AGITG 🇦🇺🇳🇿for

#ASCO25 #plenary If the graph on the left is practice changing, the graph on the right is urgently practice changing. Cost to health systems-$15K to $18K a month vs $100-$150 a month. ATOMIC trial vs CHALLENGE trial.

🤔 #neoadjuvant IO for dMMR resectable CRC? What regimen, combination and duration 🤷‍♂️? Role for Watch and Wait 👀 & Salvage Surg ✂️? OHSU Knight Cancer Institute #ASCO25 #endcancer

So you've heard the practice changing exercise CHALLENGE trial! But what did that groundbreaking exercise program actually look like day-to-day? Let's explore the "Structured Exercise Program" based on info from their paper supplement on NEJM #ASCO2025 #ASCO25 1/10

#ASCO25 This is the 1st time I started hearing the word “CURE” in patients with metastatic stage-IV cancers: ✅MSI-High cancers 🟰 #Immunotherapy 10 year survival 47% Progression beyond 2 years is exceedingly rare; a gift that keeps giving. OncoAlert ✔️Check 💯% Reflexive🔬

Colorectal cancer highlights from #ASCO25 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials. #crcsm #gicsm shorturl.at/tfZ2g

🚨 STELLAR-303 makes history! First-ever Ph3 trial to show OS benefit of IO in MSS CRC 🎯 Years of grit & belief led us here 🥹 Endless thanks to Exelixis⁩ for the trust & Dr. Hecht for leading this global win with me! 🎉 ⁦UPMC Hillman Cancer Center⁩ ir.exelixis.com/news-releases/…

Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors JAMA Oncology doi.org/10.1001/jamaon… 🔎128 studies, 343 SOTRs 👉Acute rejection: 36.2%; graft loss: 18%, lower risk w/ steroids & mTOR 👉ORR: 31% 🧐ICI my be considered in

For dMMR colon cancer, FOLFOX + atezolizumab per ATOMIC is now incorporated into the NCCN Guidelines. Mayo Clinic Comprehensive Cancer Center Alliance for Clinical Trials in Oncology The ASCO Post Colorectal Cancer Alliance Cure GI Cancers Fight Colorectal Cancer

FORTITUDE 101 is a positive Phase 3 study in FGFR2b overexpresssed gastroesophageal cancers! Looking forward to seeing the data and also for FORTITUDE 102 results with combines IO. #FGFR2b amgen.com/newsroom/press….

Its is a big and heavy hearted day for America. For many, access to lifesaving cancer care is already fragile—this makes it even harder. Its a direct threat to medicaid patients we serve- many of whom are hanging by a thread. 0/7 Here is what it means for our patients in simple

ICYMI: RWJBarnabas Rutgers Cancer Institute Director of Neuro-Oncology @moranaaa Dr. Morana Vojnic attended the closing bell ring ceremony at Nasdaq to celebrate Innovate GBM.

Hmm...